Aethlon Medical, Inc., a therapeutic medical firm, declared on Friday that its Hemopurifier, a clinical-phase immunotherapeutic device, has shown promising outcomes in an in vitro binding experiment in extricating extracellular vesicles from the plasma of cancer patients.
Ahead of the market opening on the Nasdaq, shares in Aethlon observed a staggering increase of over 101 percent, pushing share prices to $2.44.
The company confirmed that this translational research provides crucial preclinical validation supporting the proposed phase 1 clinical trials to test the safety, feasibility, and dosage of the Hemopurifier on patients with solid tumors. These patients would have shown stable or progressive disease during anti-PD-1 monotherapy treatments such as Keytruda or Opdivo.
James Frakes, the Interim CEO and CFO of Aethlon Medical expressed his pleasure with the promising data provided by this in vitro binding study on the Hemopurifier. He sees this as a significant stride for Aethlon, particularly as they approach the potential initiation of their projected phase 1 oncology trials in Australia and India.
The Hemopurifier has been designated a Breakthrough Device by the U.S. Food and Drug Administration for the use in treating those suffering from advanced or metastatic cancer and who are either unresponsive to or unable to tolerate standard care therapy.
The Hemopurifier also boasts an FDA Breakthrough Device designation and an open application for an Investigational Device Exemption, pertinent to the treatment of life-threatening viruses not covered by approved therapies.
You can find more health news like this one on rttnews.com.
